Pages that link to "Q37012207"

The following pages link to Ursodeoxycholic acid: Mechanism of action and novel clinical applications (Q37012207):

Displaying 30 items.

• Bile acids in treatment of ocular disease (Q24653326) (← links)
• Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective (Q26752931) (← links)
• Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review (Q27015735) (← links)
• Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis (Q27023986) (← links)
• RETRACTED: Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction (Q34478713) (← links)
• Tauroursodeoxycholic acid mitigates high fat diet-induced cardiomyocyte contractile and intracellular Ca2 anomalies (Q34718307) (← links)
• Colitis-associated neoplasia: molecular basis and clinical translation (Q35169025) (← links)
• Effect of Tauroursodeoxycholic Acid and 4-Phenylbutyric Acid on Metabolism of Copper and Zinc in Type 1 Diabetic Mice Model. (Q36686104) (← links)
• Efficacy and Safety of "URSA Complex" in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. (Q36705426) (← links)
• Taurine suppresses the spread of cell death in electrically coupled RPE cells (Q36950472) (← links)
• Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases (Q37009925) (← links)
• Effect of asymmetric dimethylarginine (ADMA) on heart failure development (Q37245523) (← links)
• Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial (Q37352458) (← links)
• Hepatotoxic herbs: will injury mechanisms guide treatment strategies? (Q37554889) (← links)
• Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages (Q40253244) (← links)
• Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth (Q41017557) (← links)
• Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy (Q42551875) (← links)
• Tauroursodeoxycholate counteracts hepatocellular lysis induced by tensioactive bile salts by preventing plasma membrane-micelle transition (Q42924910) (← links)
• Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells (Q45125133) (← links)
• Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review (Q51742557) (← links)
• A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. (Q53591523) (← links)
• NAD -dependent enzymatic route for the epimerization of hydroxysteroids (Q57107530) (← links)
• No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid (Q57825120) (← links)
• Effect of 4-Phenylbutyric Acid and Tauroursodeoxycholic Acid on Magnesium and Calcium Metabolism in Streptozocin-Induced Type 1 Diabetic Mice (Q59353467) (← links)
• Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model. (Q64940064) (← links)
• Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results (Q82872660) (← links)
• Diversification of host bile acids by members of the gut microbiota (Q90603645) (← links)
• Ursodeoxycholic acid (UDCA) mitigates the host inflammatory response during Clostridioides difficile infection by altering gut bile acids (Q90604249) (← links)
• Dihydroartemisinin-Bile Acid Hybridization as an Effective Approach to Enhance Dihydroartemisinin Anticancer Activity (Q91366841) (← links)
• Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis (Q91431676) (← links)